serious adverse events with Gilenya

May 2012

You'll see new warnings about serious adverse events with Gilenya.

Gilenya (fingolimod) is the first ORAL drug for reducing relapses in patients with relapsing-remitting multiple sclerosis.

But now there are reports of serious cardiac and other problems associated with Gilenya...including 15 deaths outside of Canada.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Interactions "alert fatigue" caused by the increasing number of drug interaction warnings
Antithrombotics Vitamin K will be used less often to reverse warfarin's anticoagulant effects
Dyslipidemia new cholesterol-lowering drug called Lodalis
Dyslipidemia fewer liver function tests for patients on statins
Women's Health a more tailored approach to using hormone therapy for menopausal symptoms
Multiple Sclerosis serious adverse events with Gilenya
Multiple Sclerosis Fampyra (fam-PEER-ah) for MS
Gastroenterology Health Canada is warning about serious heart problems with domperidone
Ophthalmology taking an alpha-blocker can cause serious complications years later during cataract surgery
Antithrombotics Brilinta (ticagrelor) for acute coronary syndrome
Alzheimer's Disease whether cholinesterase inhibitors (donepezil, etc) or memantine (Ebixa, etc) are helpful for Alzheimer's
Supplements raspberry ketone for weight loss